Form 4: Director Jobe Receives NHi Restricted Stock Grant

National Health Investors director James R. Jobe was granted 1,268 shares of restricted common stock, vesting in March 2027.

Summary

• James R. Jobe, a Director of National Health Investors Inc. (NHI), acquired 1,268 shares of common stock.
• The acquisition was a grant of restricted stock, with an acquisition price of $0 per share.
• These shares are scheduled to vest in full on March 3, 2027, contingent on Mr. Jobe's continued service as a director through that date.
• Following this transaction, Mr. Jobe directly owns 1,268 shares.
• Mr. Jobe also indirectly owns 33,497 shares jointly held with his spouse and 500 shares in an IRA SEP.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive event, reflecting standard director compensation practices that align leadership incentives with long-term shareholder value.

Positives

• Director James R. Jobe received a grant of 1,268 shares of restricted common stock, aligning his interests with shareholders.
• The grant vests over one year, indicating a commitment to long-term service and company performance.

Risks

• The vesting of the 1,268 restricted stock shares is subject to James R. Jobe's continued service as a director through March 3, 2027.

Future Outlook

The restricted stock grant for Director Jobe is designed to align his future incentives with the company's long-term performance, with vesting contingent on his continued service through March 2027.

Industry Context

StockSavvy.ai notes that equity grants to directors are a common practice in the healthcare REIT sector, aiming to align leadership interests with shareholder value creation. This grant to Director Jobe is consistent with typical compensation structures seen across the industry, including peers like Ventas (VTR) and Welltower (WELL), which frequently utilize restricted stock to incentivize long-term commitment.

Comparison to Industry Standards

• The grant of restricted stock to a director is a standard practice in corporate governance across various industries, including healthcare REITs, to foster long-term commitment and align interests with shareholders.
• The vesting period of one year for the restricted stock is a common duration for such grants, comparable to practices at companies like Ventas (VTR) and Welltower (WELL) for similar director compensation.

Stakeholder Impact

• Shareholders: The grant aligns Director Jobe's interests with long-term shareholder value creation.
• Director Jobe: Receives equity compensation, contingent on continued service.

Next Steps

• The restricted stock is scheduled to vest in full on March 3, 2027, subject to James R. Jobe's continued service as a director.

Key Dates

Recommendation

This Form 4 reports a routine restricted stock grant to a director, which is a standard component of executive compensation designed to align interests. It does not present new information that would fundamentally alter the investment thesis for National Health Investors Inc., thus a 'hold' recommendation remains appropriate.

Keywords

National Health Investors, NHI, Form 4, Insider Transaction, Restricted Stock, Director Compensation, Equity Grant